Comprehensive overview of consumer (patient) posts from November 2014-November 2016 from key websites.

Exact treatments covered will depend on amount and type of posts uncovered during the data collection, but search will include the below. Please note only combination therapies, new launches, and best-selling products will be included in the report (and novel launch/single product data may be limited, as it would be difficult for patients to comment about single agents vs. single-pill regimens).

  • Atripla.
  • Complera/Eviplera.
  • Descovy
  • Edurant
  • Evotaz
  • Genvoya.
  • Odefsey.
  • Prezcobix
  • Stribild.
  • Tivicay
  • Triumeq.
  • Truvada (incl. prophylaxis)
  • Vitekta

Report explains the following:

  • Sentiment toward individual treatments
  • Patient characteristics associated with each treatment
  • Clinical outcomes, side effects, and comparisons for each treatment
  • Treatment dynamics associated with obtaining and taking therapies
  • Treatment dynamics changes during the covered period

Refer to the Hepatitis C report to obtain a free sample (~10 slides) of types of data available in the report.